4.7 Article

Mild ovarian stimulation for IVF: 10 years later

期刊

HUMAN REPRODUCTION
卷 25, 期 11, 页码 2678-2684

出版社

OXFORD UNIV PRESS
DOI: 10.1093/humrep/deq247

关键词

mild ovarian stimulation; IVF; GnRH antagonist; infertility; FSH

资金

  1. Andromed
  2. Ardana
  3. Ferring
  4. Genovum
  5. Glycotope
  6. Merck Serono
  7. Organon
  8. Pantharei Bioscience
  9. Philips
  10. PregLem
  11. Schering
  12. Schering Plough
  13. Serono
  14. Wyeth
  15. IBSA
  16. Organon Schering Plough
  17. Ipsen

向作者/读者索取更多资源

Ovarian stimulation to achieve multiple follicle development has been an integral part of IVF treatment. In the context of improved laboratory performance, the need for a large number of oocytes as an integral part of a successful IVF programme may be questioned. The aim of the current debate is to summarize the studies performed during the last decade to develop the concept of mild stimulation aiming to obtain fewer than eight oocytes. Here we examine the balance between IVF success and patient discomfort, and complications and cost, and how these might improve by simpler ovarian stimulation protocols aimed at retrieving fewer oocytes. We intend to analyse why progress has been rather slow and why there is much resistance to mild stimulation. Finally, presumed useful directions for future research will be discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据